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Abstract In this study, dissolving microneedles (MNs) were
used to enhance ocular drug delivery of macromolecules.
MNs were fabricated using polyvinylpyrrolidone (PVP) poly-
mer of various molecular weights (MWs) containing three
model molecules of increasing MW, namely fluorescein sodi-
um and fluorescein isothiocyanate–dextrans (withMWof 70 k
and 150 k Da). Arrays (3 × 3) of PVPMNs with conical shape
measuring about 800 μm in height with a 300 μm base diam-
eter, containing the model drugs, were fabricated and charac-
terized for their fracture forces, insertion forces (in the sclera
and cornea), depth of penetration (using OCT and confocal
imaging), dissolution time and in vitro permeation. The aver-
age drug content of the MNs (only in MN shafts) ranged from
0.96 to 9.91 μg, and the average moisture content was below
11 %. High MW PVP produced MNs that can withstand
higher forces with minimal reduction in needle height. PVP
MNs showed rapid dissolution that ranged from 10 to 180 s,
which was dependent upon PVP’s MW. In vitro studies
showed significant enhancement of macromolecule perme-
ation when MNs were used, across both the corneal and scler-
al tissues, in comparison to topically applied aqueous solu-
tions. Confocal images showed that the macromolecules
formed depots within the tissues, which led to sustained per-
meation. However, use of MNs did not significantly benefit
the permeation of small molecules; nevertheless, MN applica-
tion has the potential for drug retention within the selected
ocular tissues unlike topical application for small molecules.
The material used in the fabrication of the MNs was found to
be biocompatible with retinal cells (i.e. ARPE-19). Overall,
this study reported the design and fabrication of minimally
invasive rapidly dissolving polymeric MN arrays which were
able to deliver high MW molecules to the eye via the
intrastromal or intrascleral route. Thus, dissolving MNs have
potential applications in enhancing ocular delivery of both
small and macromolecules.
Keywords Microneedles . Ocular drug delivery .
FITC-dextran . Cornea . Sclera . Polyvinylpyrrolidone (PVP)
Introduction
Ocular diseases such as age-related macular degeneration
(AMD), diabetic retinopathy, posterior uveitis and retinitis
due to glaucoma that affects the posterior segment of the eye
are among the leading causes of vision loss worldwide [1–3].
Other diseases such as fungal keratitis and corneal neovascu-
larization (CNV) that affect the anterior segment of the eye
can also cause visual impairment. For example, CNV is con-
sidered a serious corneal ailment that affects more than 1.4
million people in the USA and has lead to vision loss in 12 %
of them [4, 5].
Fortunately, rapid expansions of new technologies in ocu-
lar drug delivery and development of new drug candidates,
including biologics, to combat these challenging diseases
have recently emerged [6]. However, an effective drug deliv-
ery system that can selectively localize the drug within the
target ocular tissue (e.g. the sclera or cornea) in sufficient
amounts and sustain its release is still challenging for treating
ocular diseases.
The most common ocular drug delivery routes include top-
ical, systemic or local administration. However, each route has
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its own limitations. Although topical administration is the
highly preferred route to treat anterior segment diseases, the
ocular bioavailability of topically applied drugs is less than
5 % and often less than 1 %. Thus, it is difficult to achieve
therapeutic drug concentrations at the target site, for example,
in treating CNV and AMD. The poor ocular bioavailability
after topical application mainly results from the precorneal
factors such as blinking, transient residence time in the cul-
de-sac and nasolacrimal drainage. In addition, the lipoidal
nature of the corneal epithelium restricts the entry of hydro-
philic drug molecules, and the water-laden stroma acts as a
rate limiting membrane for lipophilic molecules [7].
Moreover, the physicochemical properties of the drug mole-
cule determine the diffusion resistance and relative imperme-
ability offered by various ocular tissues [8, 9]. Alternatively,
systemic or local routes have been used. Unfortunately, sys-
temic administration is not very effective due to the several
ocular-blood barriers. Thus, managing ocular disease often
requires higher dosage and frequent administration that may
result in severe adverse effects [10].
On the other hand, intraocular injections, such as intravit-
real and subconjunctival injections, have been widely used as
alternate strategies to achieve therapeutic drug concentrations
in treating ocular disorders. Particularly, intravitreal injections,
using conventional hypodermic needles, of macromolecules
such as anti-vascular endothelial growth factors (anti-VEGF)
ranibizumab (Lucentis®, 48 k Da), bevacizumab (Avastin®,
149 k Da) and aflibercept (Eylea®, 97 kDa) are commonly
practiced to treat posterior segment diseases (AMD) [11].
However, to maintain effective concentrations of these drugs
repeated injections are required, which causes discomfort to
patients and is associated with serious clinical complications
such as vitreous hemorrhage, retinal detachment, or endoph-
thalmitis [12]. Thus, an effective ocular drug delivery system
with minimal side effects is still lacking, and the great de-
mands for such an effective drug delivery system formed the
driving force for a very active research among pharmaceutical
and biomedical scientists.
In attempt to improve ophthalmic drug delivery, several
alternate approaches have been proposed and investigated in-
cluding use of microneedles (MNs). MNs are an attractive
technology in micron scale that is minimally invasive and
has been extensively investigated over the last 15 years to
enhance transdermal drug and gene delivery and monitoring
[13–15]. To date, various types of MNs have been fabricated
and tested including solid, hollow and dissolving polymeric
MNs [16–18]. Recently, attempts have been made to use the
solid and hollow MNs for ocular drug delivery. Drug-coated
solid MNs as well as hollow MNs made from a variety of
materials have been investigated to deliver model drugs of
various molecular weights (MWs), and nano- or microparti-
cles into the eye either via intracorneal or intrascleral routes
[19–22]. While various designs of MNs have been shown to
be effective in improving ocular drug delivery, some draw-
backs may impose limitations on device performance that ul-
timately constrain their applicability and efficacy. The main
drawbacks were lack of accuracy and reproducibility for drug-
coated solid MNs [19], and brittleness, complication and dif-
ficulty of fabrication and drug infusion into the ocular tissues
using silicon-made hollow and solidMNs [20, 21]. For further
information, readers are directed to read a recent review on
ocular application of MNs [23].
Interestingly, dissolving polymeric MNs have shown a
promising strategy for transdermal gene and drug delivery,
yet no data have been reported concerning their feasibility
for ocular drug delivery. Using dissolving MNs could avoid
the above-mentioned drawbacks associated with solid and
hollow MNs and minimize the solid materials burden and
the potential accidental retinal damage and detachment upon
using solid and hollowMNs. Essentially, dissolvingMNs will
soften and dissolve within the ocular tissues upon penetration
preventing highly sensitive tissues such as the retina from
damage due to mechanical forces of application.
In this study, we have investigated the potential of using
dissolving MN arrays prepared from FDA-approved biocom-
patible polymers. In this regard, we have used polyvinylpyr-
rolidone (PVP) which is an FDA-approved biocompatible
polymer and has beenwidely used as a blood plasma expander
and in pharmaceutical industry for several purposes including
as a tablet binder [24] and in fabricating dissolving MNs for
transdermal drug delivery [25–27]. We hypothesize that we
can use a simple and cost-effective method in fabrication of
rapidly dissolving MNs using biocompatible polymers that
can successfully encapsulate drugs of various MWs and to
be strong enough to penetrate the ocular tissues, and rapidly
dissolve to deliver the payload to both anterior and posterior
segments of the eye in a minimally invasive manner. To eval-
uate our hypothesis, we have used a mould-casting method in
the fabrication of a series of PVP-based dissolving MN arrays
containing representative model drugs that are commonly
employed in the treatment of eye diseases. MNs were loaded
with either low MW fluorescein sodium (FS, 376.27 Da) or a
model macromolecule i.e. fluorescein isothiocyanate (FITC)
labeled dextran of 70 kDa (FD 70) or 150 kDa (FD 150),
respectively, incorporated into the PVP gels at different con-
centrations. The feasibility of fabricating PVP-based MN ar-
rays was evaluated using PVP of various MWs i.e. PVP K15
(MW 10 k Da), PVP K30 (MW 40 k Da) or PVP K29–32
(58 k Da). The fabricated MN arrays were investigated in
terms of their mechanical strength, their ability to penetrate
the corneal and scleral tissues, dissolution kinetics, drug and
moisture content. Furthermore, the ability to deliver the model
drugs into the anterior and posterior eye segments via
intracorneal and intrascleral application was evaluated in an
in vitro study. Drug distribution within the selected ocular
tissues was also determined, and biocompatibility of the
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Fluorescein isothiocyanate–dextran with an average MW of
70,000 Da (FD 70) and 150,000 Da) were purchased from
TdBConsultancyAB (Uppsala, Sweden). Fluorescein sodium
(FS) MW 376.27 Da and polyvinylpyrrolidone (PVP K15,
MW 10,000 Da; PVP K30, MW 40,000 Da; PVP K90, MW
360,000 Da) were all purchased from Sigma–Aldrich (Dorset,
UK). Polyvinylpyrrolidone (PVP K29–32, MW 58,000 Da)
was a gift from Ashland Inc. (Surrey, UK). ARPE-19 cells
were purchased from the American Type Culture Collection.
Dulbecco’s modified Eagle’s medium/F-12 human amniotic
membrane nutrient mixture (DMEM) was purchased from
(Life technologies, UK). Fetal bovine serum (FBS) and tryp-
sin were purchased from Invitrogen Corporation (Paisley,
UK). The 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetra-
zolium bromide (MTT) cell viability reagent was purchased
from Sigma Aldrich (Dorset, UK). All other chemicals used
were of analytical reagent grade.
Drug solutions preparation
A 10 mg of FS, FD70 or FD150 were each dissolved in a
known volume of deionized water and then adjusted to 5 ml.
The solutions were left for 5 h under constant stirring of
400 rpm at room temperature and stored in a plastic caped
glass bottle covered with aluminium foil at room temperature
until further use.
Preparation of drug-loaded PVP hydrogels
PVP hydrogels were prepared in double distilled water ac-
cording to the composition presented in Table 1. A predefined
amount of polymer was added to a known volume of deion-
ized water and then vortexed for 60 s. The suspension was
then sonicated at 37 °C for 60 min and stored for overnight
hydration at room temperature. The volume of hydrogel was
then adjusted by adding the reminder of deionized water to
make the required polymer concentration and mixed vigor-
ously for homogenization forming the PVP hydrogels. These
gels were used to prepare drug-containing hydrogel formula-
tions. For this, a predetermined amount of each model drug
was added to a specified PVP hydrogel to provide a final drug
concentration of either 2 or 10 mg/g, as presented in Table 1,
and then homogeneously dispersed for 5 h using magnetic
stirring operated at 400 rpm at room temperature. The PVP/
drug hydrogel formulations were kept in cap-closed glass
container wrapped in aluminium foil at 4–8 °C until further
use. For MN baseplates, in all cases, 15 % w/w of PVP K90
hydrogels were used, as this formed mechanically strong back
support (i.e. baseplates) to the MN arrays due to its high MW,
while lower MW PVP hydrogels produced very brittle
baseplates.
Microneedles fabrication
Laser-engineered siliconemicromould templates composed of
9 (3 × 3) conical shaped needles, with an average height of
800 μm, a base width of 300 μm and an interspacing of
50 μm, were used for microfabrication of MN arrays. The
method of mould fabrication is detailed in our previous pub-
lication [28]. Briefly, approximately 100 mg of hydrogel for-
mulation of PVP (without drug) or PVP (with drug) was
poured into the silicone moulds and centrifuged for 5 min at
5000×g to form theMNs shafts alone. The needles were left to
settle and from a highly viscous gel under gentle airflow from
an electric fan for about 30 min to allow partial drying. This
was followed by adding approx. 400 mg of 15 % w/w PVP
K90 gel and centrifuged again for 5 min at 5000×g to form the
MN baseplate. This method of fabrication reduces the issue of
drug migration from MN arrays to the baseplate. Following
centrifugation, the MN arrays were dried in the moulds at
room temperature for 48 h. TheMN arrays were then carefully
removed from the molds and assessed visually for mechanical
strength and formulation homogeneity and then kept in a con-
tainer sealed with aluminium foil until use.
Preparation of ocular tissues
Ocular tissues were prepared from porcine eyeballs.
Porcine eyes have been widely used as a good model for
human eye for in vitro permeation studies. Importantly,
because they have a similar histology, collagen bundle
organization and water content to that of the human eye,
except for the sclera, which is a twofold thicker [29, 30],
porcine eyeballs for our studies were procured from a lo-
cal slaughterhouse. Eyeballs were either used within 24 h
of extraction or frozen at −80 °C until further use. After
thawing, the adherent muscle tissue was removed from the
eye bulb, and the anterior segment of the eye was
circumferentially cut behind the limbus. The eye was then
cut into two halves; the vitreous humor was removed, and
both the anterior sclera and cornea tissues were then iso-
lated by removal of the underling tissues using a cotton
swab, soaked in phosphate buffer saline (at pH 7.4) for
30 min and then blotted dry and stored in sealed container
at −80 °C until further use. The frozen tissues were used
within 3 months.
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Microneedles characterization
All fabricated MNs were characterized for a series of tests
namely for drug content, percentage moisture content, me-
chanical strength (fracture force, insertion force and depth
of penetration) and dissolution. Details of each method are
provided below:
Drug content determination MN arrays were carefully re-
moved from the baseplates, under a magnifying lens, using
scalpel and then dissolved in 5 ml of PBS at room temperature
using a magnetic stirring bar operated at 400 rpm for 30 min.
An aliquot of 150 μL was then removed and analyzed using a
fluorescence plate reader as described below. Data was report-
ed as drug weight (in μg) per array (mean ± SD, n = 3).
Moisture content determination The percentage moisture
content of the fabricated MN arrays was determined using a
Q500 ThermoGravimetric Analyser (TA Instruments, Elstree,
Herts, UK). Samples of 5–10 mg of MN arrays were heated
from ambient temperature to 150 °C at a heating rate of
10 °C/min. Nitrogen flow rates of 40 ml/min (balance purge
gas) and 60ml/min (sample purge gas) were maintained for all
samples. The data from thermogravimetric analysis experi-
ments was analyzed with TA Instruments Universal Analysis
2000 software, version 4.4 A (TA Instruments, Elstree, Herts,
UK). Moisture content was determined from calculating the
percentage of reduction in sample weight at 110 °C. Data
reported as mean ± SD, n = 3.
Determination of fracture forceMechanical strength of dis-
solving MN arrays was determined by employing a series of
predetermined forces. A TA-XT2 Texture Analyser (Stable
Microsystems, Haselmere, UK) in compression mode was
also used for this test as described previously [27]. Briefly,
MN arrays were visualized before testing using a Leica MZ6
dissection microscope (Leica Microsystems UK Ltd., Milton
Keynes, UK). Then, MNs array were carefully placed on the
flat stainless steel baseplate of the Texture Analyzer probe
with the needles pointing downwards. The probe was then
lowered at a speed of 0.1 mm/s until MNs touched a smooth
stainless steel solid block and then it exerts its predefined
force. Upon MNs solid block contact, the probe maintained
the designated force for 30 s; after which, it was moved up-
wards at a speed of 1 mm/s. MN arrays were then visualized
using the light microscope, and the MN height was measured.
The MN height displacement (mm) was then calculated and
reported as the percentage of reduction in the MN height vs
applied force. Experiments were run in triplicates.
Determination of the insertion force in ocular tissues The
insertion force of MNs into the ocular tissues was determined
using a TA-XT2 Texture Analyser (Stable Microsystems,
Haslemere, UK) as described previously [27], with minor
modifications. The scleral or corneal tissues were hydrated
for 2 h in PBS (pH 7.4) incubated in a water bath at 37 °C.
Tissues were then mounted on a wooden ball (to represent
eyeball shape) fixed underneath the Texture Analyser probe
using a metal holder. MN arrays were attached to the probe
using double-sided tape (3 M, Carrickmines, Ireland). The
Texture Analyzer was set in compression mode, and the trig-
ger force was set to 0.1 N. The probe then moved downwards
at a speed of 0.1 mm/s. Upon contact with the scleral/corneal
tissue, the probe continued to travel at the same speed until the
required insertion depth (0.8 mm) was reached while the com-
pression force was being recorded. Once the target depth was
reached, the probe was then moved upwards at a speed of
1 mm/s. Data was presented as insertion force per array vs
insertion depth. Experiments were run in triplicates.
Determination of depth of penetration in ocular tissues
Further studies were also performed to visualize and measure
the MNs depth of penetration in the ocular tissues using opti-
cal coherence tomography (OCT) (EX1301 OCTmicroscope,
Michelson Diagnostics, Kent, UK) as described previously
[28], with minor modifications. Briefly, fresh ocular tissues
were hydrated for 2 h in PBS (pH 7.4) incubated in a water
bath at 37 °C and then blotted dry. Hydrated tissues were
Table 1 Composition of
PVP-based MNs Formulation code PVP type and
concentration (%, w/w)
Model drug Drug concentration in
hydrogel (mg/g)
P1 PVP K29–32/30 – –
P2 PVP K30/40 – –
P3 PVP K15/60 – –
F1 PVP K29–32/30 FS 2
F2 PVP K29–32/30 FD70 2
F3 PVP K29–32/30 FD150 2
F4 PVP K29–32/30 FD70 10
F5 PVP K15/60 FD70 2
F6 PVP K30/40 FD70 2
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mounted on a dental wax board. Taking into consideration that
MN are rapidly dissolving which will hinder their visualiza-
tion byOCT, another layer of Parafilm®was used to cover the
ocular tissue to prevent MN dissolution upon insertion. MN
arrays were then inserted using a custom-made applicator de-
vice and visualized immediately using an EX1301 OCT
Microscope. The swept-source Fourier domain OCT system
has a laser centre wavelength of 1305.0 ± 15.0 nm, facilitating
real-time high-resolution imaging of the upper ocular layers
(7.5 μm lateral and 10.0 μm vertical resolution). The ocular
tissue was scanned at a frame rate of up to 15 B-scans (2D
cross-sectional scans) per second (scan width = 2.0 mm). The
2D images were analyzed using the imaging software ImageJ®
(National Institutes of Health, Bethesda, USA). The scale of the
image files obtained was 1.0 pixel = 4.2 μm, thus allowing
accurate measurements of the depth of MN penetration. Three
replicates were performed, and the insertion depths of 3 × 3MN
arrays were measured in total.
Dissolution of MN arrays The dissolution of the PVP-based
MN arrays with and without model drugs was investigated in
situ in both the corneal and scleral tissues. The eye tissues
were carefully cut into square pieces using a disposable scal-
pel then hydrated in PBS (pH 7.4) at a temperature of 37 °C
for 2 h. The ocular tissue specimen of either the corneal or the
scleral tissues were blotted dry and carefully secured to a
custom-made circular sheet from a weighing pan using
cynoacrylate glue (Loctite Ltd., Dublin, Ireland). These were
then placed on a dental wax board to support the eye tissue,
and then MN arrays were inserted into the centre of the tissue
using a custom-made applicator device and held there for
predefined time periods (0, 10, 20, 60, 120, 180 and 300 s).
At each time point, MNs were removed from the eye tissue,
flash frozen in liquid nitrogen and stored at −20 °C until view-
ing. MN arrays were then visualized using a Leica MZ6 dis-
section microscope (Leica Microsystems UK Ltd., Milton
Keynes, UK) fitted with a Nikon Coolpix 950 digital camera
(Nikon UK Ltd., Surrey, UK). MN heights were measured
before and after insertion. The percentage of reduction in
MN height was calculated and reported as MN height remain-
ing vs time (sec). Experiments were conducted in triplicates.
In vitro intraocular drug distribution studies
Drug distribution within the ocular tissues (i.e. the cornea and
sclera) was evaluated using two model drugs i.e. FS as a
representative for a small MW drug and FD70 as a represen-
tative for a high MW drug. Ocular tissues were prepared as
described earlier, and permeation studies were performed as
below. An aluminium foil sheet was used to separate the MN
baseplate from direct contact with the ocular tissues. Thus,
distributed drug comes only from the inserted MN arrays.
Either model drug solution or MN arrays were applied for
predefined time periods and were removed from the tissue
surface. Ocular tissues were then rinsed with fresh PBS solu-
tion, blotted dry and placed into sample blocks containing
freezing agent (OCT, Sakura Finetechnical, Tokyo, Japan)
and snap-frozen with liquid nitrogen. Each tissue sample
was sectioned into 50-μm thick pieces using a cryostat micro-
tome (Richard Allan Scientific, Kalmazoo, MI, USA) and
collected into consecutive sections onto glass slides. Tissue
sections were examined by confocal laser scanning micro-
scope (Leica TCS SP2 Confocal Microscope, Leica
Microsystems, UK) fitted with a Nikon Coolpix 950 digital
camera (Nikon UK Ltd., Surrey, UK). Z-stacks of a confocal
images were rendered into 3D mode using Volocity software
(PerkinElmer, UK) to visualize the MN penetration pathways
and the nature of drug distribution within the ocular tissues
after applying either solution or MN arrays.
In vitro permeation studies
In vitro permeation (i.e. transscleral, intrascleral, transcorneal
and intracorneal) studies were performed using modified
Franz-type diffusion cells with an effective diffusional area
of (0.6 cm2) and a receptor compartment filled with 5 ml
PBS (pH 7.4) and stirred with magnetic bar and thermostated
to 37 ± 1 °C. Either scleral or corneal tissues were mounted on
Franz-type diffusion cells and hydrated for 2 h. A volume of
10 μL of FS, 50 μL of FD 70 or FD 150 aqueous solution, at a
concentration of 2 mg/ml, or a single drug-loaded MN array
was inserted into the tissues using a custom-made applicator.
While the model drug containing MN arrays were removed
5 min after application, drug aqueous solutions were kept in
the donor compartment during the course of the permeation
study. The baseplate was separated from the corneal/scleral
tissues using aluminium foil to ensure that the permeated
model drug comes solely from the dissolving MN arrays.
The donor compartments and sampling arms were sealed using
Parafilm®. Syringes (1.0 ml) with 8.0 cm long and 20G stain-
less steel needles were used to remove 150μL from the receptor
compartment of the diffusion cells at predetermined time
points, which was replacedwith an equal volume of prewarmed
PBS. Samples were kept in the fridge for further analysis using
a fluorescence plate reader. Percentage cumulative permeation
of each drug model through the scleral/corneal tissue was de-
termined. Results were reported as mean ± SD, n = 3.
Analytical methods
Firstly, a series of dilutions (at least six dilutions) of each
model drug i.e. FS, FD 70, and FD 150 was prepared in
PBS. The fluorescent emission of an aliquot of 150 μL sample
of each drug solution was measured using a fluorescent plate
reader (BMG FLUOstar OPTIMA Microplate Reader, BMG
Labtech, Ortenberg, Germany) operated at 37 °C using 493
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and 520 nm as excitation and emission wavelengths, respec-
tively. For drug analysis, the gain was set at 1000 and 1500 for
FS and FD 70/150, respectively. Standard calibration curves
of fluorescence absorbance vs concentration (μg/ml) were
constructed and used to calculate drug concentrations in the
analyzed samples.
Biocompatibility studies
As the polymeric material and drug are deposited within the
ocular tissue following MN application, evaluating the poly-
mers compatibility with the selected ocular tissues will be a
key requirement of developing successful MN formulation.
Therefore, PVP’s ocular cells biocompatibility study was per-
formed on human retinal pigment epithelial (ARPE-19) cells.
For this, PVP K29/32 was dissolved in cell culture medium at
various concentrations (1, 2, 3 and 4 mg/ml) and was filter-
sterilized using a 0.2-μm filter. ARPE-19 cells were seeded at
a density of 20,000 cells per well onto 96-well tissue culture
plates (VWR, Leicestershire, England, UK) for 24 h prior to
the assay. On the following day, 200 μL cell culture medium
was removed and replaced with 200 μL of PVP K29/32 solu-
tions at different concentrations. Cells were then returned to
the incubator for 24 h. The cells were viewed and images were
recorded using an inverted microscope at predefined times 0,
2, 4, 6 and 24 h after polymer solution application. To assess
cell viability, cell monolayers were washed with 200 μL ster-
ile PBS (pH 7.4) and were then replenished with MEM-
containing MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) reagent at 1 mg/ml. The cells were then
returned to the incubator for a final 2 h. The MTT assay is a
gold standard assay for determining cell viability and is based
on the ability of viable cells to reduce the water-soluble MTT
to a water-insoluble formazan product. The plates were shak-
en for 2 min to assist solubilization, before 200 μL aliquots
were transferred to duplicate wells of a 96-well microplate for
absorbance measurement. The absorbance was measured at
450 nm. The measured absorbance values were expressed as
a percentage of the control untreated cells, defined as 100 %
viable. The experiment was repeated on three consecutive
days. Data was reported as mean ± SD, n = 3.
Statistical analysis
Where appropriate, data was analyzed using the Student t test,
one-way ANOVA with post-hoc comparisons or Mann–
Whitney U-test. In all cases, statistical significance was de-
fined at the standard 5 % level. Microsoft Excel 11.0
(Microsoft) and GraphPad Prism Version 4.0 (GraphPad
Prism Software Inc., San Diego, CA, USA) were used to
analyze data.
Results and discussion
Recently, drug-coated solid as well as hollowMNsmade from
a variety of materials have been investigated to deliver model
drugs of various MWs, and nano- or microparticles into the
eye either via intracorneal or intrascleral routes [19–21, 22].
Drug-coated stainless steel solid MN was able to deliver only
69 % of the applied dose. The rest of the dose either remained
adherent to the MN which was likely due to the incomplete
MN insertion into the tissue or may have deposited on the
scleral surface affecting dose accuracy and reproducibility
[19]. Solid silicon or hollow glass-based MNs are intrinsically
brittle and can be broken off accidently during application
(thereby remaining in the tissue), and fabrication of these
needles is rather complicated and expensive. Furthermore,
hollow MNs cannot deliver solutions without MN retraction
or use of tissue dissolving enzymes to provide free space for
accommodating drug solution that requires careful infusion at
a predetermined rate. Drug solution infusion through MNs
also requires operation at high pressures (250–300 kPa),
which in turn is related to the viscosity of the solution and
the geometric properties of the MNs [20, 21]. Uncontrolled
retraction from the sclera could lead to removal of theMN and
leakage of the drug onto the scleral/corneal surface affecting
the amount of drug delivered. Thus, special insertion devices
and infusion systems are required to enable MN injection in a
controlled manner. Consequently, there is a distinct need for
the development of other types of MNs to address these short-
comings. Therefore, this study used PVP-based dissolving
polymeric MNs.
A wide range of polymers has been used to fabricate dis-
solving MN arrays including polyvinylpyrrolidone (PVP)
[31]. PVP is a homopolymer formed by the monomer N-vi-
nyl-2-pyrrolidone. It is an FDA-approved biocompatible poly-
mer and has been widely used as a blood plasma expander and
in pharmaceutical industry for several purposes including as a
tablet binder [24] and in fabricating dissolving MNs for trans-
dermal drug delivery [25–27]. Its wide use can be attributed to
a number of properties, including excellent water solubility,
biological compatibility, low toxicity, film forming and adhe-
sion, complexing ability, inert behavior towards salts and
acids and resistance to thermal degradation in solution [32].
One of the enticing properties of using PVP as the struc-
tural material for polymeric MNs is the ability for rapid
dissolution within the biological tissues due to the high
water solubility, which is deemed essential for ocular
drug delivery as it is very challenging to apply the MNs
patch on the eye for long periods of time. FS and FITC-
conjugated dextrans have been widely used as model
molecules in investigations of permeation across ocular
tissues, and it was deemed to be stable and reliable
tracers [33–35]. Therefore, we have used these molecules
in our study as model compounds.
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Microneedles characterization
In literature, some studies have reported using PVP to prepare
dissolving MN arrays e.g. PVP K29/32 hydrogel at 40 % w/v
[27] or 50 % w/v of either PVP K15 or PVP K29/32 hydrogel
[36]. In this study, PVP MN arrays prepared from various
MWs were found to be sufficiently rigid from all tested PVP
hydrogel formulations. The microscopic inspection of the fab-
ricated MN arrays (Fig. 1) revealed that conical-shaped MN
arrays (3 × 3) with sharp tips were formed that were around
780 ± 60 μm in height, 300 ± 40 μm in base width and 50 μm
of interspacing between the MNs. However, higher polymer
concentrations were required to fabricate MNs from low MW
PVP hydrogels. The required polymer concentration used in
the preparation of hydrogels from PVP K15, PVP K30 and
PVP K29–32 were 60, 40 and 30 % w/v, respectively.
Essentially, we were also able to encapsulate the three model
drugs, with increasing MWs and at different concentrations
within the MN arrays, while maintaining their mechanical
properties (discussed later). However, it was noticed that using
the same PVP hydrogels to form the MN baseplates produced
very brittle and fragile MN baseplates. Therefore, a high MW
PVP (i.e. PVP K90) hydrogel prepared at 15 % w/v was used
to from a more a resilient and rigid baseplate for all the MNs
tested in this study.
To ensure dosage accuracy and reproducibility, the drug
content of MNs was determined (Table 2). Drug recovery
from MNs was found to range from 92 ± 5 % to 97 ± 4 %.
As shown in Table 2, the content of drug in theMN arrays (i.e.
total amount present in nine needles) ranged from 0.96 ± 0.13
to 9.91 ± 0.28 μg for different MN formulations. Importantly,
it is of great interest that we were able to incorporate approx-
imately 1.3 and 10 μg of a high MWmolecule (i.e. FD 70) in
the PVPMNs when loaded at 2 and 10 mg/ml, respectively. A
similar trend was noticed for other model drugs. Thus, dis-
solving MNs could be used to deliver clinically relevant doses
of highly potent highMWanti-VEGF drugs such as Avastin®
(bevacizumab, ≈149 kDa). For example, a study by Kim et al.
[37] concluded that a dose of 4.4 μg of bevacizumab is needed
to provide the same effect as that of 2.5 or 52.5 mg when
delivered via the subconjunctival route or eye drops to treat
CNV. Moreover, increasing the number of MN arrays can
further increase drug content in the PVP MNs. However, it
is important to remember that high density of MNs, unlike
for transdermal application, can impair MN penetration into
ocular tissues due to its curved surface or a bed of nail effect
can occur.
Moisture content plays an important factor on mechanical
properties of the MNs including rigidity, flexibility and disso-
lution kinetics within the ocular tissues that in turn effects drug
stability and efficacy. High content of moisture will impair
MNs ability to penetrate the tissues. In general, the moisture
content of the MN arrays ranged from 7.21 ± 0.65 to
10.53 ± 1.03 %, which is dependent upon the PVP MW and
type and concentration of the encapsulated drug, as shown in
Table 2. Any level of moisture can affect the stability of drug
molecules; however, this is particularly important for bio-
logics that are high sensitive to moisture. Although these
MN arrays were fabricated under normal lab conditions, fab-
rication of these MNs in a controlled environment (tempera-
ture and humidity) followed by low-temperature drying can
further decrease the moisture content of MNs thereby enhanc-
ing the storage stability of biomolecules. Nevertheless, at
these moisture levels, we found that the MNs maintained
their mechanical strength and effectively penetrated the
ocular tissues.
MN arrays were also tested for intraocular insertion forces.
Prior to this, the isolated porcine corneal and scleral tissues
Fig. 1 Light microscopy images
of MN arrays prepared by using
various PVP/drug hydrogel
formulations: a F1, b F2, c F3, d
F4, e F5 and f F6
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were measured for thickness after hydration for 2 h. The av-
erage thickness was found to be 950 ± 70 and 700 ± 300 μm,
for the cornea and sclera, respectively. Therefore, the MN
height was chosen to be 800 μm to allow intrascleral or
intracorneal drug delivery using MN arrays. Applying the
MN arrays onto the tissues requires an appropriate force to
enable MN penetration which should be maintained until MN
array is completely dissolved to deliver its payload into the
tissue. Literature review revealed no data has been reported
concerning the required force for intraocular MN arrays inser-
tion. Therefore, this study endeavoured to measure the re-
quired force (N) to insert MN arrays into either the corneal
or scleral tissues in vitro. The applied insertion force/array vs
MN insertion depth is reported in Fig. 2. In general, the fab-
ricated MN arrays were sufficiently rigid to be inserted into
the ocular tissues. In both ocular tissues, the required force to
insert the 3 × 3 MN array was proportional to the insertion
depth. This is can be attributed to the conical shape of MNs,
where the MN diameter increase from tip to base thereby
requiring higher forces with an increase in the depth of pene-
tration. Interestingly, the required force to insert the MN array
into the corneal tissue was higher than that for the scleral
tissue. For example, the average insertion force required to
fully insert the MN array into the corneal tissue was 3.72 N/
9 MNs, which was nearly threefold higher than that required
to be fully inserted into the scleral tissue (1.34 N/ 9MNs).
Thus, the required insertion force per single MN is 0.41 and
0.15 N for the cornea and sclera, respectively.
In the literature, forces to penetrate various areas of the eye
wall using hypodermic needle were reported [38, 39]. For
example, Matthews et al. reported scleral penetration forces
of around 1.0 N, when a single 18 G hypodermic needle with
an outer diameter (OD) of 1.27 mm was used. However, the
force required to penetrate the central cornea was significantly
lower than all other areas i.e. around 0.5 N [38]. Although this
contradicts our data, this study was conducted on the human
eyeballs, unlike the porcine tissues reported in our study.
Tissue type (porcine vs human) and intraocular pressure play
a great role in defining the insertion forces. It is well docu-
mented that the cornea also has highly ordered parallel fibrils
that make the tissue highly resistant to deformation at raised
intraocular pressure. Upon the application of a tensile stress, a
restoring force is generated by the stretched fibers that bal-
ances the applied force and resists deformation, providing the
cornea with substantial tensile strength [40]. Thus, higher in-
sertion force is required in the cornea compared to the sclera.
But this can be explained on the basis that Matthews et al.
have used hypodermic needles which differed from our study
in relation to materials, dimensions and geometrics. Pulido
et al. found peak needle penetration forces for the anterior
sclera of 0.29 and 0.61 N with 30 G (OD 310 μm) and 27G
(OD 410 μm) needles, respectively [39]. The 30 G hypoder-
mic needle is very closely related to our fabricated dissolving
MNs in its OD, which is around 300 μm. However, the re-
quired insertion force was twofold higher than in our case.
This can be attributed to the fact that our MNs are of conical
shape while the hypodermic needles are of cylindrical
shape. Thus, our MNs allow minimally invasive means of
drug delivery.
Further studies were performed to evaluate the ability of
MN arrays to penetrate through the ocular tissues using OCT
scanning. Images of MN arrays following their in vitro inser-
tion into porcine corneal and scleral tissues are shown in
Fig. 3. A previous report has shown that only 200 μm of the
650 μm height of a PVP-based 100-MN array was inserted
into cadaver porcine skin [26]. Interestingly, the results here
clearly demonstrate that all fabricated MN arrays from the
Table 2 Drug and moisture content of MNs. Mean ± SD, n = 3
MN array code Drug content (μg/array) Moisture content (%)
F1 1.02 ± 0.18 7.64 ± 0.23
F2 1.31 ± 0.12 10.53 ± 1.03
F3 1.31 ± 0.17 10.26 ± 0.84
F4 9.91 ± 0.28 8.03 ± 0.23
F5 1.03 ± 0.18 9.89 ± 0.97



















































Fig. 2 Graphical representation
of the average depth of insertion
vs forces applied for a 3 × 3 MN
array (F2) into a the corneal and b
the scleral tissues. Mean ± SD,
n = 3
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three different PVP polymers i.e. PVP K15, PVP K30 and
PVP K29–32 were strong enough to penetrate the ocular tis-
sues in vitro without bending or breaking. The insertion depth
was around 75 ± 10.8 % (n = 3) of the total MN height (data
not presented). This can be attributed to that of our MN
arrays as they are composed of fewer MNs (only nine
MNs) with different geometrics, and the use of ocular tis-
sues instead of skin, which has differed mechanical proper-
ties. The partial insertion of MNs can be ascribed to the use
of the highly elastic Parafilm® layer (to avoid dissolution
of MNs during imaging) hindering the MN arrays from
being fully inserted into the ocular tissue. However, this
should not be of great concern due to the fact that in real
situations, MN arrays will be applied directly into the ocu-
lar tissues without any barrier. Thus, high percentage
(>75 %) of MN insertion will be expected.
The ability of dissolvingMN arrays to withstand the forces
required for insertion into the designated biological tissue or
any additional accidental forces while inserting is the key
factor in their successful development and application.
Mechanical strength of the dissolving MN arrays is widely
affected by several factors including polymer type and con-
centration, moisture content, encapsulated drug type and con-
centration and preparation methods [26, 41]. Therefore, in this
study, we evaluated the mechanical strength (fracture force) of
those MN arrays prepared from either both plain PVP and
PVP/drug hydrogel formulations. A Texture Analyser (in
compression mode) was used to apply predefined forces in-
cluding those required for MN insertion and other higher
forces (1.5, 3, 6 and 9 N). The percentage of MN height
reduction was calculated and plotted against the applied com-
pression force and is presented in Fig. 4. Images of some
samples MN arrays after applying predefined forces are pre-
sented in Fig. 5.
As represented in Figs. 4 and 5, PVP polymers at the spec-
ified hydrogel concentrations can form sufficiently rigid but
brittle MN arrays. PVP K15 produced the most brittle MN
arrays that showed around 18 % reduction in the MN height
at a force of 3 N/array, but PVP K30 and PVP K29/32 MNs
showed around 12.9 and 12.4 % reduction in height when
exposed to the same force. Additionally, data shows that there
is a proportional relationship between the applied compres-
sion force and the percentage of reduction in the MN height,
and this is more profound in MN arrays fabricated from PVP
K15. PVP K29/32 (P1) formed the most rigid and least brittle
MN arrays, which can withstand high forces with minimal
height reduction. For example, applying forces between 1.5
and 9 N/array caused an average height reduction from 5 to
32 %. PVP K30 (P2) comes second in MN rigidity. However,
no significant (p > 0.05) difference in the mechanical strength
(fracture force) was noted between MN arrays when fabricat-
ed from PVP K30 or PVP K29/32 hydrogels. This can be
ascribed to that both polymers have an intermediate and close-
ly related MW i.e. 40 k and 58 k Da, respectively.
Interestingly, encapsulated model drugs of different MWs at
a concentration of 2 mg/ml in hydrogel did not significantly
affect the mechanical properties when low compression forces
were applied such as 1.5 and 3 N/array. However, the effect was
more profound with high compression forces such as 6 or 9 N/
array. But statistically no significant difference (p > 0.05) was
found among the three model drugs in terms of the effect on the
mechanical strength within the same MNs and at same concen-
tration (Figs. 4b and 5). On the other hand, increasing the en-





Fig. 3 Sample OCT images of
MN arrays inserted into a porcine
(i) corneal and (ii) scleral tissue
prepared from different PVP
hydrogels namely (a) F2, (b) F5,
and (c) F6
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arrays produced a gradual decrease in the mechanical strength
of the MNs. For example, applying 3 N/array on MN arrays
containing no drug, FD 70 at 2 mg/ml or FD 70 at 10 mg/ml,
caused a height reduction of around 12.4 ± 2.5, 12.4 ± 3.5 and
15.7 ± 2.3 %, respectively. This can be attributed to a possible
interaction between the FD 70 and the PVP polymer whichmay
affect the polymer configuration upon recrystallization during
the drying process. Our PVP K29/32-based MNs were still
significantly stronger than other PVP-based MNs reported
in literature, where Sullivan et al. found the fracture force
of MNs to be 0.13 ± 0.03 N per needle [26]. This might be
due to the method of MN fabrication which employed the
polymerization technique.
Understanding the behavior of MN after insertion into the
ocular tissue is essential in the design and development of an
effective MN array and to determine optimal conditions in
terms of the MN application method. Therefore, the dissolu-
tion kinetics of the PVP-based MN arrays was evaluated fol-
lowing insertion into the porcine ocular tissues, as shown in
Fig. 6. Although, the water content of porcine corneal tissue
(around 78 %) is higher than sclera tissue (around 71 %) [28,
42, 43], our data showed that the PVP-based MN arrays dis-
solved faster in the scleral tissues (Figs. 6 and 7b) than in the
cornea (Figs. 6 and 7a). This could be due to the lipoidal
nature of the corneal epithelium, and it is also depended upon
the degree of hydration of the tissues prior to experimental
setup. With regard to the effect of PVP’s MWon the dissolu-
tion rate, results indicate MNs fabricated from PVP K15 were
completely dissolved within 30 s following insertion into the
sclera and less than 60 s in the cornea. Interestingly, within the
first 10 s of insertion, around 80 and 60 % of the PVP K15-
based MNs was dissolved within the sclera and cornea. PVP
K30-based MN arrays dissolved in similar fashion but at
slower rate in comparison with those MN arrays fabricated
from PVP K15. In contrast, PVP K29/32-based MN arrays
completely dissolved within 120 and 180 s following insertion
into the porcine scleral and corneal tissues, respectively.
Therefore, given the similarity of porcine and human ocular
tissues, we expect that our MN dissolution in the human eye
could also be occur within similar magnitude.
Our data revealed that PVP-based MNs dissolve faster in
ocular tissues than in the skin. This was expected in comparison
to the data in literature, if we take into account that the ocular
tissues vary in their properties and water content compared to



























































































Applied compression force (N)
P1 F2 F4
Fig. 4 Graphs representing the average percent reduction in MN height
vs predefined compression forces. MN arrays were fabricated either from
a plain PVP hydrogels i.e. P1, P2 and P3, b drug-loaded PVP MNs i.e.
F1, F2 and F3 (at a concentration of 2 mg/ml). c PVP K29/32-based MN
arrays encapsulating the model drug FD 70 at a concentration of either 0
(P1), 2 (F2) or 10 mg/ml (F4). Data reported as mean ± SD, n = 3
Fig. 5 Sample images of PVP K29/32-based MN arrays encapsulating FD 70 at a concentration of 2 mg/ml, before and after applying predefined
compression forces (in N), the applied forces are a 0 N/array, b 1.5 N/array, c 3 N/array and d 9 N/array
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cadaver porcine skin, PVP-based dissolving MNs showed sig-
nificant dissolution within 1 min, and after 5 min, the MNs
were 89 % (by mass) dissolved [25]. With regard to the effect
of the encapsulated drug type and concentration on the disso-
lution behaviour of the fabricated MN arrays, results (not pre-
sented) indicated that drug MW at low concentrations
(2 mg/ml) had no significant effect. However, increasing FD
70 concentration from 2 to 10 mg/ml resulted in faster dissolv-
ingMN arrays. Overall, results revealed that PVP K29/32MNs
provide rapid dissolution in ocular tissues, which make them as
a possible candidate in the fabrication of MN arrays for ocular
application. However, using PVP K15 MNs are not feasible as
MN arrays could dissolve very quickly even before complete
insertion into the ocular tissues thereby depositing its payload
on the ocular tissue surface instead within the tissue.
In vitro intraocular drug distribution studies
In addition to insertion of MNs into the tissues, it is also
essential to get insight into drug distribution within the ocular
tissue after application. Therefore, in this study, the fluores-
cently conjugated model drugs were traced within the ocular
tissue using scanning confocal microscopy, as shown in
Figs. 9 and 10. Results showed thatMN arrays fabricated from
PVP K29/32 polymer were able to penetrate both the porcine
sclera and cornea. Although, the MN heights are around
800 μm, they did not completely pierce either ocular tissue.
This can be seen clearly in Figs. 8c and 9c. It suggests that
dissolving MNs start dissolving as soon as they are inserted
into the ocular tissues and do not pierce it completely (as
proven in OCT studies). This is consistent with our findings
a 
b 
t0= 0 sec t1= 10 sec t2= 60 sec t3= 120 sec
Fig. 7 Representative digital images of PVP K29/32-basedMN arrays encapsulating FD 70 at a concentration of 2 mg/ml before and after insertion into















































Fig. 6 Percentage of remainingMNs heights vs dissolution time of PVP-
based MN arrays encapsulating the model drug FD 70 after insertion for
predefined times into porcine ocular tissues; a the corneal tissues, b the
scleral tissues. MN arrays were fabricated using various PVP/drug
hydrogel formulations: PVP K29/32/ FD70 (F2); PVP K29/32/ FD70
(F4); PVP K30/ FD70 (F5); PVP K15/ FD70 (F6). Data reported as
mean ± SD, n = 3
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from dissolution studies in the previous section where we
found that more than 20 and 40 % of the MNs dissolved
within 10 s after insertion either in the cornea or in the sclera.
This could be of great benefit, as there will be no concerns of
causing damage to the innermost sensitive ocular tissues such
as the choroid/retina beneath the scleral tissue. Furthermore,
the confocal images show that macromolecules such as FD 70
cannot permeate easily through the scleral or corneal tissues.
This can be clearly concluded from images of the corneal and
scleral tissues after 1 h from application of FD 70 aqueous
solution (Figs. 8d and 9d). Our findings completely agree with
data reported in literature that the cornea and sclera form a
strong barrier to molecules larger than 5 k Da. Therefore, large
molecules such as FD 70 are more likely to accumulate in the
outer surface of the sclera and cornea, when they are applied
topically [45–47]. Essentially, as we can see in Fig. 9a,
dissolving MNs were able to penetrate the epithelium (outer
layer of the cornea with thickness of around 50 μm), which is
Fig. 9 Schematic diagram on the left hand side represents the collection
and processing of confocal images of scleral tissues following application
of FD70-loaded PVP K29/32 MN arrays (F2), where a topical image of
tissue after 5 min following insertion of MN array, b cross-section image
of tissue after 5 min following MN array insertion, c topical image at a
depth of 80 μm from surface of the tissue after 1 h following MN inser-
tion and d cross section image of tissue 1 h after applying an aqueous
solution of FD 70 (at 2 mg/ml)
Fig. 8 Schematic diagram on the
left hand side represents the
collection and processing of
confocal images of the corneal
tissue following application of
FD70-loaded PVP K29/32 MN
arrays (F2), where confocal
images represents a after 5 min of
MN application, b topical image
at a depth of 80 μm from surface
of the tissue after 1 h following
MN array insertion, c cross-
section image of tissue after 1 h
following MN array insertion and
d cross-section image of tissue
after 1 h applying an aqueous
solution of FD 70 (at 2 mg/ml)
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deemed the main barrier for transcorneal drug permeation and
then reached the stroma and dissolved to release the payload
that led to formation of drug depot (Fig. 8b, c). Similarly,
dissolving MNs were able to penetrate the scleral tissue
(Fig. 9a, b) to form a drug depot within the tissue that diffused
to the other side of the sclera (Fig. 9c).
In terms of the small MW hydrophilic model drugs (i.e.
FS), MN arrays successfully delivered the drug into the ocular
tissues (data not shown), which then distributed evenly within
the tissue. However, no significant difference was seen in
distribution of FS within the tissues from either inserting
MNs containing FS or application of FS aqueous solution
topically. Our finding are in agreement with data reported in
literature that FS, a water-soluble compound with a MW of
376 Da, penetrates into and permeates across both the corneal
epithelial and scleral membrane [45–47]. Thus, using dissolv-
ing MN arrays to deliver such hydrophilic drugs with small
MW do not offer great advantages in comparison to topical
drops, apart from increasing their retention time in the ocular
tissue. Accordingly, dissolving MN arrays could be useful in
facilitating delivery of macromolecules by two mechanisms.
For macromolecules, by bypassing the main barrier for their
permeation either across the epithelium in cornea or in the
sclera and reducing the diffusion time through the ocular tis-
sues and by increasing their retention time in the tissue thereby
preventing their removal by blinking and tear secretion upon
topical application. And, for small molecules, MNs can in-
crease their retention time in the ocular tissues.
In vitro permeation studies
Taking into consideration the properties of rapidly dissolving
MN arrays fabricated, from the three PVP polymers i.e. PVP
K15, PVP K30 and PVP K29/32, we have selected PVP K29/
32 MNs to investigate the efficiency for ocular drug delivery
via intrastromal and intrascleral application. Drug permeation
studies were performed using either these MN arrays or
predefined volume of the respective drug aqueous solutions.
Data concerning drug permeation profiles through the cornea
and sclera are presented in Figs. 10 and 11, respectively.
For the small MW molecule (i.e. FS), a high permeation
(Figs. 10a and 11a) was seen across the corneal and scleral
tissues. The percentage permeation across the sclera was near-
ly the same from either topically applied aqueous solution or
following MN application. For example, 86 and 99 % of FS
permeated after 24 h from MNs or solution, respectively. In
contrast, the percentage permeation across the cornea was
significantly higher for the topically applied aqueous solution
(79 %) when compared to MNs (53 %). In general, the drug
first permeated and increased at a constant rate until 6 h, after
which the drug permeation rate decreased significantly. This
could be due to FS binding strongly to the scleral and corneal
tissues. The binding was likely to be mediated through ionic
interactions since fluorescein has three dissociation constants
that correspond to its three pKa values: 2.13, 4.44 and 6.36,
respectively. At pH 7.4, the anionic forms of FS may have
bound to positively charged extracellular matrix molecules
(e.g. collagens) and proteins dissolved in interstitial fluid.
The binding may effectively reduce the flux of FS in tissues.
Our observations are consistent with other literature data [47].
Furthermore, FS diffusion through the corneal tissue from
insertedMNswas slower than the topically applied drug aque-
ous solution. This suggests that PVP polymer from dissolved
MNs may encapsulate the drug reducing its diffusion from
stroma to the endothelium thus permeation into the receptor
solution thereby showing a sustained release profile.
For macromolecules such as FD 70 and FD 150, topically
applied aqueous solutions showed high resistance in perme-
ation across both the scleral and corneal tissues (Figs. 10 and
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FD 150 MN (F3)
Fig. 10 Graphical representation of in vitro permeation profiles through
the corneal tissue from either aqueous solution or PVPK29/32-basedMN
arrays of three model drugs namely a FS, b FD 70 and c FD 150
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both the cornea and sclera when compared to FD 150. For
example, the average percentage permeation of aqueous solu-
tions of FD70 and FD150 was 9 and 5 % across the corneal
tissues. In contrast, average percentage permeation of aqueous
solutions of FD 70 and FD 150 was 45 and 6 % across the
scleral tissues. Concerning the effect of MNs in enhancing the
transocular permeation of both macromolecules, our results
indicate that dissolving MN arrays have significantly en-
hanced transocular delivery of both model macromolecules
in comparison with aqueous solutions. The percentage drug
delivered through the cornea for FD 70 from topically applied
aqueous solutions was 9%which increased to 83% after 48 h.
Likewise, permeation of FD 150 increased from 5 to 61 %.
This suggests that dissolving MN arrays played a significant
role in enhancing delivery into the corneal stroma and formed
a depot, but the endothelium is still forming a strong barrier.
Thus, the drug MW still plays its role in dictating transcorneal
permeation. However, intrastromal delivery can be an excel-
lent target in the treatment of corneal diseases such as CNV.
On the other hand, increasing the drug concentration of FD 70
in the dissolving MN arrays by fivefold (2 to 10 mg/ml) did
not significantly increase the percentage permeation. In the
sclera, dissolving MNs improved delivery of both small and
macromolecule drugs. For the macromolecules, i.e. FD 70 and
FD 150, dissolving MNs successfully delivered the total ap-
plied doses from both molecules.
Biocompatibility
PVP polymer is considered to be biologically inert. In this
study, we investigated the biocompatibility of PVP polymer
with ARPE cells. Cells were exposed to a range of polymer
concentrations (at 0.5, 1, 2, 3 and 4 mg/ml) to mimic a sce-
nario of retinal cells-polymer exposure upon delivering the
polymer in the scleral tissue. The percentage viability was
found to be >83 % at all concentrations below 2 mg/ml
(Fig. 12), which concludes that PVP K29/32 MNs is non-
toxic in an in vitro testing to the retinal cells, therefore,
deemed as biocompatible. However, cell viability was signif-
icantly inhibited when cells were treated with 3 (p = 0.031)
and 4 mg/ml (p = 0.041) of PVP. This could be primarily due
to excess amount of material that could have inhibited normal
cell growth.
Conclusion
This study, for the first time, demonstrated the design and
fabrication of rapidly dissolving MN arrays to overcome the
barrier function of ocular tissues in order to improve ocular
drug delivery. In doing so, a simple and cost-effective mould-
casting method was developed that utilizes the relatively eco-
nomic biocompatible polymer, PVP, inMN fabrication. Of the
three PVP MWs (i.e. PVP K15, PVP K30 and PVP K29/32)
investigated, PVP K29/32-based MNs were able to withstand
the higher compression force required for insertion in the oc-
ular tissues with minimal reduction in needle height without
fracturing or bending and dissolved in the ocular tissues with-
in less than 3 min. These MNs were able to encapsulate either
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FD 150 MN (F3)
Fig. 11 Graphical representation of in vitro permeation profiles through
the scleral tissue from either aqueous solution or PVP K29/32-based MN


















Fig. 12 Graphical representation of percent retinal cell counts in cell
cultures impregnated with predefined amounts of PVP K29/32 in cell
culture media of a 0.5, 1, 2, 3 and 4 mg/ml
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150,000 Da. In vitro studies showed that MNs penetrated into
the ocular tissues could rapidly dissolve to form a depot within
the tissues and showed a higher degree of permeation of high
MWmodel molecules and sustained their release. This can be
considered of great importance for delivery of high MWanti-
VEGF drugs in a minimally invasive manner. Additionally,
the material used in the fabrication of MNs was found to be
biocompatible to retinal cells. Because MNs dissolve in the
ocular tissue fluid, there is no sharps waste, which makes
dissolving MNs impossible to reuse and thereby eliminates
the risks of biohazard sharps, unlike intravitreal injections that
use hypodermic needles. Further studies are required to inves-
tigate the feasibility of using this platform to deliver active
therapeutic proteins such bevacizumab, ranibizumab or
aflibercept which are used in the treatment of posterior
(AMD) and anterior (CNV) ocular diseases.
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